We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00004669
First Posted: February 25, 2000
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Penn State University
Information provided by:
Office of Rare Diseases (ORD)
February 24, 2000
February 25, 2000
December 9, 2005
June 1996
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia
Not Provided

OBJECTIVES: I. Estimate the efficacy of cortisol replacement therapy during the first 12 days of life for prevention of bronchopulmonary dysplasia.

II. Estimate the effect of cortisol replacement therapy on the signs of acute adrenal insufficiency.

III. Evaluate the effects of cortisol replacement therapy on adrenal hormone concentrations and on the ability of the adrenal gland to respond to ACTH.

IV. Determine the effect of this replacement therapy on markers of inflammation in lung lavage fluid and peripheral blood leukocytes.

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Hydrocortisone therapy IV or placebo begins no later than 48 hours after birth and continues every 12 hours for 12 days. Hydrocortisone is given at 2-4 times the basal cortisol secretion rate.

Tracheal lavage on intubated babies is performed at start of study and on day 4 of life to assess concentrations of inflammatory markers.

If larger babies show appropriate response to ACTH by 15-17 days and the less mature babies show a decreased response, then a longer course of therapy is proposed for future studies.

Interventional
Phase 2
Primary Purpose: Prevention
Bronchopulmonary Dysplasia
Drug: hydrocortisone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
Not Provided
Not Provided

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • At risk for development of bronchopulmonary dysplasia

--Patient Characteristics--

  • Hematopoietic: No congenital sepsis
  • Hepatic: No structural defect of liver
  • Renal: No agenesis or structural defect of a kidney
  • Cardiovascular: No structural defect of the heart
  • Metabolic: No diabetic mothers (e.g., preexisting insulin dependent, noninsulin dependent, and gestational diabetes)
  • Pulmonary: No structural defect of the lung
  • Other: Newborn birth weight must be 500 to 999 g and have endotracheal tubes in place at 12 hours of age Eligible if treatment can be given before 48 hours of postnatal life No major congenital anomaly causing significant defect in major organ system
Sexes Eligible for Study: All
up to 1 Year   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00004669
199/12016
PENN-420633
Not Provided
Not Provided
Not Provided
Not Provided
National Center for Research Resources (NCRR)
Penn State University
Study Chair: Kristi L. Watterberg Penn State University
Office of Rare Diseases (ORD)
December 2001

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top